View
214
Download
0
Category
Preview:
DESCRIPTION
Asclep Pharma REport
Citation preview
Confidentiality Agreement
The undersigned reader acknowledges that the information provided by _______________ in this
business plan is confidential; therefore, reader agrees not to disclose it without the express written
permission of _______________.
It is acknowledged by reader that information to be furnished in this business plan is in all respects
confidential in nature, other than information which is in the public domain through other means and
that any disclosure or use of same by reader, may cause serious harm or damage to
_______________.
Upon request, this document is to be immediately returned to _______________.
___________________
Signature
___________________
Name (typed or printed)
___________________
Date
This is a business plan. It does not imply an offering of securities.
Table of Contents
Page 1
1.0 Executive Summary ......................................................................................................................................1
Chart: Highlights ..............................................................................................................................1
1.1 Objectives ...........................................................................................................................................1
1.2 Mission ................................................................................................................................................1
1.3 Keys to Success..................................................................................................................................1
2.0 Company Summary ......................................................................................................................................2
2.1 Company Ownership ..........................................................................................................................2
2.2 Start-up Summary ...............................................................................................................................2
Table: Start-up .................................................................................................................................2
Chart: Start-up .................................................................................................................................3
3.0 Products ........................................................................................................................................................3
4.0 Market Analysis Summary ............................................................................................................................3
4.1 Market Segmentation ..........................................................................................................................3
Table: Market Analysis ....................................................................................................................4
Chart: Market Analysis (Pie) ...........................................................................................................4
4.2 Target Market Segment Strategy .......................................................................................................4
4.3 Industry Analysis .................................................................................................................................4
4.3.1 Competition and Buying Patterns ..........................................................................................4
5.0 Strategy and Implementation Summary .......................................................................................................5
5.1 SWOT Analysis ...................................................................................................................................5
5.1.1 Strengths ................................................................................................................................5
5.1.2 Weaknesses ..........................................................................................................................5
5.1.3 Opportunities ..........................................................................................................................5
5.1.4 Threats ...................................................................................................................................5
5.2 Competitive Edge ................................................................................................................................5
5.3 Marketing Strategy ..............................................................................................................................5
5.4 Sales Strategy .....................................................................................................................................6
5.4.1 Sales Forecast .......................................................................................................................6
Table: Sales Forecast ...........................................................................................................6
Chart: Sales Monthly .............................................................................................................6
Chart: Sales by Year .............................................................................................................7
5.5 Milestones ...........................................................................................................................................7
Table: Milestones ............................................................................................................................7
Chart: Milestones ............................................................................................................................8
6.0 Management Summary ................................................................................................................................8
6.1 Personnel Plan ....................................................................................................................................9
Table: Personnel .............................................................................................................................9
7.0 Financial Plan ...............................................................................................................................................9
7.1 Start-up Funding .................................................................................................................................9
Table: Start-up Funding ................................................................................................................10
7.2 Important Assumptions .....................................................................................................................10
7.3 Break-even Analysis .........................................................................................................................10
Table: Break-even Analysis ..........................................................................................................10
Chart: Break-even Analysis ...........................................................................................................11
7.4 Projected Profit and Loss ..................................................................................................................11
Table: Profit and Loss ...................................................................................................................12
Chart: Profit Monthly .....................................................................................................................12
Chart: Profit Yearly ........................................................................................................................13
Chart: Gross Margin Monthly ........................................................................................................13
Chart: Gross Margin Yearly...........................................................................................................14
7.5 Projected Cash Flow .........................................................................................................................14
Table: Cash Flow ..........................................................................................................................15
Chart: Cash ...................................................................................................................................16
Table of Contents
Page 2
7.6 Projected Balance Sheet ..................................................................................................................16
Table: Balance Sheet ....................................................................................................................17
7.7 Business Ratios ................................................................................................................................17
Table: Ratios .................................................................................................................................18
Table: Sales Forecast .........................................................................................................................................1
Table: Personnel .................................................................................................................................................2
Table: Profit and Loss .........................................................................................................................................3
Table: Cash Flow ................................................................................................................................................4
Table: Balance Sheet .........................................................................................................................................5
ASCLEP PHARMA
Page 1
1.0 Executive Summary
1.1 Objectives
1. To deliver the medicines and surgical supplies to the retailers such us hospitals , clinics
and medical shops .
2. To establish ourself as a premier pharmaceutical distributing company by 2020
1.2 Mission
ASCLEP Pharma offers pharmaceutical , biotechnological and medical device manufactures a
reliable , high quality alternative way for sales and marketing of the products. ASCLEP pharma
improves the return on sales and marketing investment by accelerating the physician learning curve
on prelaunch, new, and existing products. In addition,ASCLEP will benefit small and innovative
biotechnology and pharmaceutical companies that do not have an extensive sales force to cover
Kerala especially in southern districts like Trivandrum, Kollam,Pathanamthitta. Alappuzha &
Kottayam.
1.3 Keys to Success
ASCLEP PHARMA
Page 2
2.0 Company Summary
ASCLEP Pharma is a pharamaceutical Distribution Company which is providing high level expertise
in the marketing and selling of pharmaceutical products. The company's headquarters is in
Pathanamthitta Kerala India
2.1 Company Ownership
ASCLEP Pharma is under mutual partnership of
1. Dr Hassan Mohammed Aziz
2. Mr Arun Kumar MJ
3. Mr Shameer A
4. Mr Fayush Yonus
Each of the share holders holds 25% of shares of the company and the profit share of each share
holder is 25% of total net profit.
2.2 Start-up Summary
The table below illustrates a complete breakdown of all start-up assets that are needed, as total
start-up requirements. Currently, we have no short-term liabilities.
Table: Start-up
Start-up
Requirements
Start-up Expenses
Legal $30,000
Stationery $5,000
Insurance $10,000
Rent $10,000
Other $10,000
Total Start-up Expenses $65,000
Start-up Assets
Cash Required $100,000
Start-up Inventory $200,000
Other Current Assets $0
Long-term Assets $0
Total Assets $300,000
Total Requirements $365,000
ASCLEP PHARMA
Page 3
3.0 Products
The products that ASCLEP Pharma offers
1. Medicines
2. Medical Equipments
3. Surgical Instruments
4.0 Market Analysis Summary
Currently, the largest market segment is the pharmaceutical industry. We have a huge opportunity
in this segment. ASCLEP Pharma is fully concenterated in Hospitals Clinics and Medical shops in
southern districts of Kerala such as Pathanamthitta , Kollam, Thiruvananthapuram , Alappuzha &
Kottayam in the first two years and we will extend the demographics regions such
as Ernakulam , Thrissur, Koazhikode & Malappuram .
Before 2020 we will acquire the distribution for all demographics regions of the Kerala.
4.1 Market Segmentation
Conduct the Market Study??????????????????????????????????
ASCLEP PHARMA
Page 4
Table: Market Analysis
Market Analysis
Year 1 Year 2 Year 3 Year 4 Year 5
Potential Customers Growth CAGR
Hospitals 50% 20 30 45 68 102 50.28%
Clinics 50% 25 38 57 86 129 50.72%
Medical Shops 50% 100 150 225 338 507 50.06%
Total 50.20% 145 218 327 492 738 50.20%
4.2 Target Market Segment Strategy
Conduct Study ....................Discuss with Partners
Dr Hassan 's PART
4.3 Industry Analysis
To be analysed......................................
4.3.1 Competition and Buying Patterns
Buying Patterns ......Competitions ..................To Be Analaysed .....
Primary data
Pathanamthitta
ASCLEP PHARMA
Page 5
1. MALANADU PHARMACEUTICALS
Kozhencherry, Pathanamthitta
2. M/S Suraj Pharma
Thiruvalla, Pathanamthitta
3. Samsons
Kozhencherry, Pathanamthitta
4. Pharma Traders
Thiruvalla, Pathanamthitta
5. M M Drug Links
Thiruvalla, Pathanamthitta
5.0 Strategy and Implementation Summary
5.1 SWOT Analysis
Have a chat with partners..................
5.1.1 Strengths
Have a chat with partners..................
5.1.2 Weaknesses
Have a chat with partners..................
5.1.3 Opportunities
Have a chat with partners..................
5.1.4 Threats
Have a chat with partners..................
5.2 Competitive Edge
Have a chat with partners..................
5.3 Marketing Strategy
Have a chat with partners..................
Have a chat with partners..................
ASCLEP PHARMA
Page 6
5.4 Sales Strategy
To be Checked with Hassan ..................
5.4.1 Sales Forecast
Table: Sales Forecast
Sales Forecast
Year 1 Year 2 Year 3
Sales
Medicines $300,000 $450,000 $600,000
Surgical Instruments $300,000 $450,000 $600,000
Total Sales $600,000 $900,000 $1,200,000
Direct Cost of Sales Year 1 Year 2 Year 3
Cost of Goods Medicines $180,000 $270,000 $405,000
Cost of Goods Surgical Supplies $180,000 $270,000 $405,000
Transportation Costs $60,000 $90,000 $120,000
Subtotal Direct Cost of Sales $420,000 $630,000 $930,000
ASCLEP PHARMA
Page 7
5.5 Milestones
Have a chat with partners..................
Table: Milestones
Milestones
Milestone Start Date End Date Budget Manager Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Name me 5/8/2015 6/7/2015 $0 ABC Department
Totals $0
ASCLEP PHARMA
Page 8
6.0 Management Summary
ASCLEP Pharma is a Parnership firm formed by 4 partners who are excelled in four different
segments.
1 DR Hassan Mohammed Aziz MBBS
Chairman of the company who is a graduate in medical science , practicing as a Junior Doctor in
various hospitals. He posses the Head of Marketing department of the company
2 Mr Fayush Yonus MBA
Managing Director of the company who is graduated in human resourse and marketing, worked
as Administration Manager in UAE and as credit officer in Standard Chartered Bank India.
3 Mr Arun Kumar MJ BCom
Head of Finance Department of the company,who have an immense experience in accounting and
banking sector ,wo
4 Mr Shameer A NeBosh
Head of HR department , who have an immense experience in EMAAR Group ,Dubai ,UAE
ASCLEP PHARMA
Page 9
6.1 Personnel Plan
Table: Personnel
Personnel Plan
Year 1 Year 2 Year 3
HR Department $0 $0 $0
Finanace Department $0 $0 $0
Marketing Department $0 $0 $0
Total People 0 0 0
Total Payroll $0 $0 $0
7.0 Financial Plan
7.1 Start-up Funding
ASCLEP PHARMA
Page 10
Table: Start-up Funding
Start-up Funding
Start-up Expenses to Fund $65,000
Start-up Assets to Fund $300,000
Total Funding Required $365,000
Assets
Non-cash Assets from Start-up $200,000
Cash Requirements from Start-up $100,000
Additional Cash Raised $0
Cash Balance on Starting Date $100,000
Total Assets $300,000
Liabilities and Capital
Liabilities
Current Borrowing $0
Long-term Liabilities $0
Accounts Payable (Outstanding Bills) $0
Other Current Liabilities (interest-free) $0
Total Liabilities $0
Capital
Planned Investment
Owner $0
Investor $0
Additional Investment Requirement $365,000
Total Planned Investment $365,000
Loss at Start-up (Start-up Expenses) ($65,000)
Total Capital $300,000
Total Capital and Liabilities $300,000
Total Funding $365,000
7.2 Important Assumptions
7.3 Break-even Analysis
Table: Break-even Analysis
Break-even Analysis
Monthly Revenue Break-even $0
Assumptions:
Average Percent Variable Cost 70%
Estimated Monthly Fixed Cost $0
ASCLEP PHARMA
Page 11
7.4 Projected Profit and Loss
ASCLEP PHARMA
Page 12
Table: Profit and Loss
Pro Forma Profit and Loss
Year 1 Year 2 Year 3
Sales $600,000 $900,000 $1,200,000
Direct Cost of Sales $420,000 $630,000 $930,000
Other Costs of Sales $0 $0 $0
Total Cost of Sales $420,000 $630,000 $930,000
Gross Margin $180,000 $270,000 $270,000
Gross Margin % 30.00% 30.00% 22.50%
Expenses
Payroll $0 $0 $0
Marketing/Promotion $0 $0 $0
Depreciation $0 $0 $0
Rent $0 $0 $0
Utilities $0 $0 $0
Insurance $0 $0 $0
Payroll Taxes $0 $0 $0
Other $0 $0 $0
Total Operating Expenses $0 $0 $0
Profit Before Interest and Taxes $180,000 $270,000 $270,000
EBITDA $180,000 $270,000 $270,000
Interest Expense $0 $0 $0
Taxes Incurred $54,000 $81,000 $81,000
Net Profit $126,000 $189,000 $189,000
Net Profit/Sales 21.00% 21.00% 15.75%
ASCLEP PHARMA
Page 13
ASCLEP PHARMA
Page 14
7.5 Projected Cash Flow
ASCLEP PHARMA
Page 15
Table: Cash Flow
Pro Forma Cash Flow
Year 1 Year 2 Year 3
Cash Received
Cash from Operations
Cash Sales $600,000 $900,000 $1,200,000
Subtotal Cash from Operations $600,000 $900,000 $1,200,000
Additional Cash Received
Sales Tax, VAT, HST/GST Received $0 $0 $0
New Current Borrowing $0 $0 $0
New Other Liabilities (interest-free) $0 $0 $0
New Long-term Liabilities $0 $0 $0
Sales of Other Current Assets $0 $0 $0
Sales of Long-term Assets $0 $0 $0
New Investment Received $0 $0 $0
Subtotal Cash Received $600,000 $900,000 $1,200,000
Expenditures Year 1 Year 2 Year 3
Expenditures from Operations
Cash Spending $0 $0 $0
Bill Payments $349,650 $784,831 $1,088,958
Subtotal Spent on Operations $349,650 $784,831 $1,088,958
Additional Cash Spent
Sales Tax, VAT, HST/GST Paid Out $0 $0 $0
Principal Repayment of Current Borrowing $0 $0 $0
Other Liabilities Principal Repayment $0 $0 $0
Long-term Liabilities Principal Repayment $0 $0 $0
Purchase Other Current Assets $0 $0 $0
Purchase Long-term Assets $0 $0 $0
Dividends $0 $0 $0
Subtotal Cash Spent $349,650 $784,831 $1,088,958
Net Cash Flow $250,350 $115,169 $111,042
Cash Balance $350,350 $465,519 $576,561
ASCLEP PHARMA
Page 16
7.6 Projected Balance Sheet
ASCLEP PHARMA
Page 17
Table: Balance Sheet
Pro Forma Balance Sheet
Year 1 Year 2 Year 3
Assets
Current Assets
Cash $350,350 $465,519 $576,561
Inventory $80,000 $219,375 $318,699
Other Current Assets $0 $0 $0
Total Current Assets $430,350 $684,894 $895,260
Long-term Assets
Long-term Assets $0 $0 $0
Accumulated Depreciation $0 $0 $0
Total Long-term Assets $0 $0 $0
Total Assets $430,350 $684,894 $895,260
Liabilities and Capital Year 1 Year 2 Year 3
Current Liabilities
Accounts Payable $4,350 $69,894 $91,260
Current Borrowing $0 $0 $0
Other Current Liabilities $0 $0 $0
Subtotal Current Liabilities $4,350 $69,894 $91,260
Long-term Liabilities $0 $0 $0
Total Liabilities $4,350 $69,894 $91,260
Paid-in Capital $365,000 $365,000 $365,000
Retained Earnings ($65,000) $61,000 $250,000
Earnings $126,000 $189,000 $189,000
Total Capital $426,000 $615,000 $804,000
Total Liabilities and Capital $430,350 $684,894 $895,260
Net Worth $426,000 $615,000 $804,000
7.7 Business Ratios
ASCLEP PHARMA
Page 18
Table: Ratios
Ratio Analysis
Year 1 Year 2 Year 3 Industry Profile
Sales Growth n.a. 50.00% 33.33% 0.00%
Percent of Total Assets
Inventory 18.59% 32.03% 35.60% 0.00%
Other Current Assets 0.00% 0.00% 0.00% 100.00%
Total Current Assets 100.00% 100.00% 100.00% 100.00%
Long-term Assets 0.00% 0.00% 0.00% 0.00%
Total Assets 100.00% 100.00% 100.00% 100.00%
Current Liabilities 1.01% 10.21% 10.19% 0.00%
Long-term Liabilities 0.00% 0.00% 0.00% 0.00%
Total Liabilities 1.01% 10.21% 10.19% 0.00%
Net Worth 98.99% 89.79% 89.81% 100.00%
Percent of Sales
Sales 100.00% 100.00% 100.00% 100.00%
Gross Margin 30.00% 30.00% 22.50% 0.00%
Selling, General & Administrative Expenses 9.00% 9.00% 6.75% 0.00%
Advertising Expenses 0.00% 0.00% 0.00% 0.00%
Profit Before Interest and Taxes 30.00% 30.00% 22.50% 0.00%
Main Ratios
Current 98.93 9.80 9.81 0.00
Quick 80.54 6.66 6.32 0.00
Total Debt to Total Assets 1.01% 10.21% 10.19% 0.00%
Pre-tax Return on Net Worth 42.25% 43.90% 33.58% 0.00%
Pre-tax Return on Assets 41.83% 39.42% 30.16% 0.00%
Additional Ratios Year 1 Year 2 Year 3
Net Profit Margin 21.00% 21.00% 15.75% n.a
Return on Equity 29.58% 30.73% 23.51% n.a
Activity Ratios
Inventory Turnover 4.31 4.21 3.46 n.a
Accounts Payable Turnover 81.38 12.17 12.17 n.a
Payment Days 27 16 26 n.a
Total Asset Turnover 1.39 1.31 1.34 n.a
Debt Ratios
Debt to Net Worth 0.01 0.11 0.11 n.a
Current Liab. to Liab. 1.00 1.00 1.00 n.a
Liquidity Ratios
Net Working Capital $426,000 $615,000 $804,000 n.a
Interest Coverage 0.00 0.00 0.00 n.a
Additional Ratios
Assets to Sales 0.72 0.76 0.75 n.a
Current Debt/Total Assets 1% 10% 10% n.a
Acid Test 80.54 6.66 6.32 n.a
Sales/Net Worth 1.41 1.46 1.49 n.a
Dividend Payout 0.00 0.00 0.00 n.a
Appendix
Page 1
Table: Sales Forecast
Sales Forecast
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Sales
Medicines $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000
Surgical Instruments $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000
Total Sales $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000
Direct Cost of Sales Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Cost of Goods Medicines $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000
Cost of Goods Surgical Supplies $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000
Transportation Costs $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000
Subtotal Direct Cost of Sales $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000
Appendix
Page 2
Table: Personnel
Personnel Plan
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
HR Department $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Finanace Department $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Marketing Department $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total People 0 0 0 0 0 0 0 0 0 0 0 0
Total Payroll $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Appendix
Page 3
Table: Profit and Loss
Pro Forma Profit and Loss
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Sales $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000
Direct Cost of Sales $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000
Other Costs of Sales $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Cost of Sales $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000
Gross Margin $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000
Gross Margin % 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00%
Expenses
Payroll $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Marketing/Promotion $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Depreciation $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Rent $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Utilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Insurance $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Payroll Taxes 15% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Other $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Operating Expenses $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Profit Before Interest and Taxes $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000
EBITDA $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000
Interest Expense $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Taxes Incurred $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500
Net Profit $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500
Net Profit/Sales 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00%
Appendix
Page 4
Table: Cash Flow
Pro Forma Cash Flow
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Cash Received
Cash from Operations
Cash Sales $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000
Subtotal Cash from Operations $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000
Additional Cash Received
Sales Tax, VAT, HST/GST Received 0.00% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
New Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
New Other Liabilities (interest-free) $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
New Long-term Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Sales of Other Current Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Sales of Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
New Investment Received $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Subtotal Cash Received $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000
Expenditures Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Expenditures from Operations
Cash Spending $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Bill Payments $150 $4,500 $4,500 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167
Subtotal Spent on Operations $150 $4,500 $4,500 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167
Additional Cash Spent
Sales Tax, VAT, HST/GST Paid Out $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Principal Repayment of Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Other Liabilities Principal Repayment $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Long-term Liabilities Principal Repayment $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Purchase Other Current Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Purchase Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Dividends $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Subtotal Cash Spent $150 $4,500 $4,500 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167
Net Cash Flow $49,850 $45,500 $45,500 $45,500 $42,167 ($51,167) $45,500 $42,167 ($51,167) $45,500 $42,167 ($51,167)
Cash Balance $149,850 $195,350 $240,850 $286,350 $328,517 $277,350 $322,850 $365,017 $313,850 $359,350 $401,517 $350,350
Appendix
Page 5
Table: Balance Sheet
Pro Forma Balance Sheet
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Assets Starting Balances
Current Assets
Cash $100,000 $149,850 $195,350 $240,850 $286,350 $328,517 $277,350 $322,850 $365,017 $313,850 $359,350 $401,517 $350,350
Inventory $200,000 $165,000 $130,000 $95,000 $60,000 $125,000 $90,000 $55,000 $120,000 $85,000 $50,000 $115,000 $80,000
Other Current Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Current Assets $300,000 $314,850 $325,350 $335,850 $346,350 $453,517 $367,350 $377,850 $485,017 $398,850 $409,350 $516,517 $430,350
Long-term Assets
Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Accumulated Depreciation $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Assets $300,000 $314,850 $325,350 $335,850 $346,350 $453,517 $367,350 $377,850 $485,017 $398,850 $409,350 $516,517 $430,350
Liabilities and Capital Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Current Liabilities
Accounts Payable $0 $4,350 $4,350 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350
Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Other Current Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Subtotal Current Liabilities $0 $4,350 $4,350 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350
Long-term Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Liabilities $0 $4,350 $4,350 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350
Paid-in Capital $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000
Retained Earnings ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000)
Earnings $0 $10,500 $21,000 $31,500 $42,000 $52,500 $63,000 $73,500 $84,000 $94,500 $105,000 $115,500 $126,000
Total Capital $300,000 $310,500 $321,000 $331,500 $342,000 $352,500 $363,000 $373,500 $384,000 $394,500 $405,000 $415,500 $426,000
Total Liabilities and Capital $300,000 $314,850 $325,350 $335,850 $346,350 $453,517 $367,350 $377,850 $485,017 $398,850 $409,350 $516,517 $430,350
Net Worth $300,000 $310,500 $321,000 $331,500 $342,000 $352,500 $363,000 $373,500 $384,000 $394,500 $405,000 $415,500 $426,000
Recommended